However, it is likely that patients with MG and thymoma represent a distinct clinical subgroup among the CV2/CRMP5‐IgG PND, with an overall better prognosis compared to those with SCLC and/or CNS manifestations. This evidence concerns the gene DPYSL5 and thymoma.